These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27255581)

  • 1. Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing".
    Reig M; Torres F; Mariño Z; Forns X; Bruix J
    J Hepatol; 2016 Oct; 65(4):864-865. PubMed ID: 27255581
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing.
    Cammà C; Cabibbo G; Craxì A
    J Hepatol; 2016 Oct; 65(4):861-862. PubMed ID: 27255578
    [No Abstract]   [Full Text] [Related]  

  • 3. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Osaki Y; Kojima Y; Nakata R; Goto T; Takehiro A; Kimura H; Mitsuda A; Kawanami C; Uchida Y; Ogawa C; Kusakabe A; Narita R; Ide Y; Abe T; Tsuji K; Kitamura T; Okada K; Sohda T; Shigeno M; Satou T; Izumi N
    PLoS One; 2018; 13(4):e0194704. PubMed ID: 29659591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
    Conti F; Buonfiglioli F; Scuteri A; Crespi C; Bolondi L; Caraceni P; Foschi FG; Lenzi M; Mazzella G; Verucchi G; Andreone P; Brillanti S
    J Hepatol; 2016 Oct; 65(4):727-733. PubMed ID: 27349488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.
    Cabibbo G; Petta S; Calvaruso V; Cacciola I; Cannavò MR; Madonia S; Distefano M; Larocca L; Prestileo T; Tinè F; Bertino G; Giannitrapani L; Benanti F; Licata A; Scalisi I; Mazzola G; Cartabellotta F; Alessi N; Barbàra M; Russello M; Scifo G; Squadrito G; Raimondo G; Craxì A; Di Marco V; Cammà C;
    Aliment Pharmacol Ther; 2017 Oct; 46(7):688-695. PubMed ID: 28791711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV-Related Cirrhosis. Are Outcomes Different after Direct Antiviral Agents? A Review.
    Spârchez Z; Mocan T
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):403-410. PubMed ID: 29253056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
    ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr
    J Hepatol; 2016 Oct; 65(4):734-740. PubMed ID: 27288051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.
    Yang JD; Aqel BA; Pungpapong S; Gores GJ; Roberts LR; Leise MD
    J Hepatol; 2016 Oct; 65(4):859-860. PubMed ID: 27392425
    [No Abstract]   [Full Text] [Related]  

  • 11. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct antiviral agents against hepatitis C virus: Beneficial or harmful?
    Murcia Ó; Carnicer F; Gómez-Escolar L; Miralles C; Griñó MP; Barquero Martín C; Pascual S
    J Hepatol; 2018 Apr; 68(4):844-845. PubMed ID: 29100994
    [No Abstract]   [Full Text] [Related]  

  • 13. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?
    Zavaglia C; Okolicsanyi S; Cesarini L; Mazzarelli C; Pontecorvi V; Ciaccio A; Strazzabosco M; Belli LS
    J Hepatol; 2017 Jan; 66(1):236-237. PubMed ID: 27592303
    [No Abstract]   [Full Text] [Related]  

  • 14. Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Ikeda K; Kawamura Y; Kobayashi M; Kominami Y; Fujiyama S; Sezaki H; Hosaka T; Akuta N; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Dig Dis Sci; 2017 Oct; 62(10):2932-2942. PubMed ID: 28884320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction?
    Alberti A; Piovesan S
    Liver Int; 2017 Jun; 37(6):802-808. PubMed ID: 28544696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV clearance by direct antiviral therapy and occurrence/recurrence of hepatocellular carcinoma: A "true-or-false game".
    Russo FP; Bruno S; Farinati F
    Dig Liver Dis; 2017 Apr; 49(4):321-325. PubMed ID: 28187979
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.
    Petta S; Cabibbo G; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Tovoli F; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Felder M; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Boccaccio V; Craxì A; Bruno S; Trevisani F; Cammà C;
    Aliment Pharmacol Ther; 2017 Jan; 45(1):160-168. PubMed ID: 27790734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
    Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
    World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
    Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
    Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.